Prospective Registration of Severe Pneumocystis Jiroveci Pneumonia Requiring ICU Admission

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-07-01

Study Completion Date

2019-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

the investigators aim to set up a multicenter registry study for severe PJP requiring ICU admission. The purpose of this study is

1. to establish a prospective severe PJP registry about clinical characteristics, laboratory and radiographic findings, critical care management and outcomes.
2. to explore the predictive factors associated with outcomes ;
3. to compare the difference between PJP patients with HIV and without HIV infection.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pneumocystis jiroveci pneumonia (PJP) is a common opportunistic infection in immunocompromised patients. Although the mortality of patients with mild to moderate PJP has declined substantially, the reported outcomes of severe PJP requiring ICU admission, especially with mechanical ventilation are grave. The data on this group of patients is very limited and mainly comes from retrospective studies.

the investigators aim to set up a multicenter registry study for patient with severe PJP requiring ICU admission to provide comprehensive descriptive data on diagnosis, clinical course, critical care management and outcomes in a large cohort.

All patients with PJP admitted to the participating ICU during a two-year period will be enrolled. The CRF will be made available to the participating sites as a printable paper-based CRF.

The following individual patient data for study participants will be collected:

* General demographic information
* Presence of risk factors for PJP and comorbid condition
* use of prophylactic SMZ/TMP, immunosuppressive medications prior to ICU admission
* Information about PJP and co-infection diagnosis
* vital signs, laboratory(blood serum and BALF sample) and radiologic data at ICU admission and during ICU stay
* organ failures and severity of the disease at admission, new onset of organ failures during ICU stay
* Medications for PJP, time course and modalities and settings for respiratory support
* ICU, 28-day mortality, hospital, 90-day mortality

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pneumocystis Jiroveci Pneumonia Intensive Care Unit

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients with PJP

PJP patients in ICU with or without HIV infection

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosis with PJP, confirmed by PCR or methenamine silver stain of sample from BALF, aspirate or sputum;
* ICU admission due to PJP-related respiratory failure

Exclusion Criteria

* NO

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bin Du, Dr

Role: STUDY_DIRECTOR

Peking Union Medical College Hospital

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

jinmin Peng, Dr.

Role: CONTACT

Phone: 86-010-69155036

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PJP2017-1

Identifier Type: -

Identifier Source: org_study_id